share_log

Nova Leap Health Corp. Provides Guidance of Record Adjusted EBITDA for Q2 2023 and Change of CFO

Nova Leap Health Corp. Provides Guidance of Record Adjusted EBITDA for Q2 2023 and Change of CFO

Nova Leap Health Corp. 提供2023年第二季度調整後息稅折舊攤銷前利潤創紀錄以及首席財務官變更的指導
GlobeNewswire ·  2023/08/03 04:30

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

不得在美國境內傳播或分發給美國新聞通訊社

HALIFAX, Nova Scotia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or "the Company"), a growing home health care organization, is announcing a change in Chief Financial Officer ("CFO"). The Company is also providing a financial update ahead of its second quarter 2023 results expected to be released on August 10, 2023. All amounts are in United States dollars unless otherwise specified.

新斯科舍省哈雷法克斯,2023年8月2日(環球通訊社)-Nova Leap Health Corp.(多倫多證券交易所股票代碼:NLH)(“Nova Leap”或“本公司”),一家成長中的家庭保健組織,宣佈更換首席財務官(CFO)。該公司還在2023年第二季度業績預計於2023年8月10日公佈之前提供最新的財務情況。除非另有說明,所有金額均以美元計算。

Q2 2023 Financial Update

2023年第二季度財務更新

Based on currently available information, the Company is providing the following guidance for its second quarter ended June 30, 2023. The Company expects:

根據目前掌握的資訊,該公司為截至2023年6月30日的第二季度提供以下指導。該公司預計:

  • An increase in quarterly revenue, an increase in quarterly gross margin percentage, record quarterly Adjusted EBITDA for the U.S. operating segment and record quarterly consolidated Adjusted EBITDA;
  • Q2 2023 revenues of $6,677,000, an increase of 4.4% relative to Q1 2023 revenues;
  • A continued increase in gross margin as a percentage of revenue to 36.8%;
  • Record quarterly Adjusted EBITDA for the U.S. operating segment of $597,000, an increase of 90% relative to Q1 2023;
  • Q2 2023 consolidated Adjusted EBITDA of $386,000, an amount 4.5X higher than Q1 2023 Adjusted EBITDA of $86,025 and the best in Company history; and
  • Head office and operations management expenses of $1,526,000, a decrease of 6.5% from Q1 2023 due to management's continued streamlining of operations.
  • 季度收入增加,季度毛利率百分比增加,美國運營部門創紀錄的季度調整後EBITDA和創紀錄的季度合併調整後EBITDA;
  • 2023年第二季度收入為6,677,000美元,比2023年第一季度收入增長4.4%;
  • 毛利率佔收入的比例繼續提高至36.8%;
  • 美國運營部門創紀錄的季度調整後EBITDA為597,000美元,比2023年第一季度增長90%;
  • 2023年第二季度合併調整後EBITDA為386,000美元,是2023年第一季度調整後EBITDA 86,025美元的4.5倍,是公司歷史上最好的;以及
  • 總部及營運管理開支為1,526,000美元,較2023年第一季減少6.5%,原因是管理層繼續精簡營運。

Change in CFO

首席財務官的變動

With a great deal of gratitude and respect, the Company announces Lisette Hachey has resigned from the roles of CFO & Corporate Secretary, effective immediately, as part of a planned transition. Ms. Hachey, who has been with the Company over two and half years, was appointed CFO & Corporate Secretary in June 2022 and had previously held the roles of Corporate Controller and Director of Finance.

懷著極大的感激和敬意,公司宣佈,作為計劃交接的一部分,利塞特·哈奇已辭去首席財務官兼公司祕書一職,立即生效。哈奇女士已經在公司工作了兩年半,於2022年6月被任命為首席財務官兼公司祕書,此前曾擔任過公司財務總監和董事財務總監。

Chris LeBlanc, previously Nova Leap's Director of Finance, has been appointed CFO and Corporate Secretary, effective immediately. Chris has twenty years of progressive experience, including seven years in a publicly traded company, and has a strong background in financial management, including financial reporting, budgeting, financial analysis and treasury functions.

曾任董事財務總監的克裡斯·勒布朗被任命為首席財務官兼公司祕書,即刻生效。Chris擁有20年的發展經驗,其中包括在一家上市公司工作的7年,並在財務管理方面擁有強大的背景,包括財務報告、預算、財務分析和財務職能。

President & CEO's Comments

總裁&首席執行官點評

"I would like to thank Lisette for her work with Nova Leap during these past two and a half years," said Chris Dobbin, president & CEO of Nova Leap. "We have benefitted from her experience and, with the disclosure of our upcoming record results, she leaves Nova Leap on a high note. I would also like to congratulate Chris on his appointment. Chris has played an important role since joining Nova Leap over a year ago and has the necessary leadership qualities required as we continue building Nova Leap."

Nova Leap首席執行官兼首席執行官克裡斯·多賓說:“我要感謝麗賽特在過去兩年半裡為Nova Leap所做的工作。我們從她的經驗中受益良多,隨著我們即將創紀錄的業績的披露,她高調地離開了Nova Leap。我也想祝賀Chris的任命。自從一年多前加入Nova Leap以來,Chris發揮了重要作用,並擁有我們繼續建設Nova Leap所需的必要領導素質。

About Nova Leap

關於Nova Leap

Nova Leap is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #42 ranking on the 2021 Report on Business ranking of Canada's Top Growing Companies, the #2 ranking on the 2020 Report on Business ranking of Canada's Top Growing Companies and the #10 Ranking in the 2019 TSX Venture 50 in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 10 different U.S. states within the New England, Southeastern, South Central and Midwest regions as well as in Nova Scotia, Canada.

Nova Leap是一家收購意識很強的家庭保健服務公司,業務領域是美國和加拿大增長最快的行業之一。該公司在以個人和家庭為中心的連續護理中發揮著至關重要的作用,特別是那些需要痴呆症護理的人。Nova Leap在2021年加拿大最具成長性公司商業排名報告中排名第42位,在2020年加拿大最具成長性公司商業排名報告中排名第2,在2019年多倫多證券交易所清潔技術和生命科學領域風險投資50強中排名第10。該公司的地理位置多樣化,在美國新英格蘭、東南部、中南部和中西部地區的10個不同州以及加拿大的新斯科舍省開展業務。

NON-IFRS AND OTHER MEASURES:

非國際財務報告準則和其他措施:

This release contains references to certain measures that do not have a standardized meaning under IFRS as prescribed by the International Accounting Standards Board ("IASB") and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement IFRS measures by providing a further understanding of operations from management's perspective. Accordingly, non-IFRS financial measures should not be considered in isolation or as a substitute for analysis of financial information reported under IFRS. The Company presents non-IFRS financial measures, specifically Adjusted EBITDA (as such term is hereinafter defined), as well as supplementary financial measures such as annualized revenue. The Company believes these non-IFRS financial measures are frequently used by lenders, securities analysts, investors and other interested parties as a measure of financial performance, and it is therefore helpful to provide supplemental measures of operating performance and thus highlight trends that may not otherwise be apparent when relying solely on IFRS financial measures.

本新聞稿提及某些措施,這些措施在國際會計準則委員會(“IASB”)規定的“國際財務報告準則”中沒有標準化含義,因此不太可能與其他公司提出的類似措施相比較。相反,這些措施是作為補充資訊提供的,以便從管理層的角度進一步瞭解業務情況,從而補充《國際財務報告準則》的措施。因此,不應孤立地考慮非《國際財務報告準則》財務措施,也不應將其作為根據《國際財務報告準則》報告的財務資訊分析的替代辦法。本公司提出非國際財務報告準則財務指標,特別是調整後的EBITDA(該術語在下文中定義),以及諸如年化收入等補充財務指標。本公司認為,貸款人、證券分析師、投資者和其他相關方經常使用這些非IFRS財務指標作為財務業績的衡量標準,因此,提供經營業績的補充指標是有幫助的,從而突出了在單純依賴IFRS財務指標時可能不明顯的趨勢。

Adjusted Earnings before interest, taxes, amortization and depreciation ("Adjusted EBITDA"), is calculated as income from operating activities plus amortization and depreciation and stock-based compensation expense. The most directly comparable IFRS measure is income from operating activities.

調整後的扣除利息、稅項、攤銷和折舊前的收益(“調整後的EBITDA”)按經營活動的收入加上攤銷和折舊以及基於股票的薪酬支出計算。“國際財務報告準則”最直接的可比性指標是經營活動的收入。

FORWARD LOOKING INFORMATION:

前瞻性資訊:

Certain information in this press release may contain forward-looking statements, such as statements regarding future expansions and cost savings and plans regarding future acquisitions and business growth, including anticipated annualized revenue or annualized recurring revenue run rate growth and anticipated consolidated Adjusted EBITDA margins. This information is based on current expectations and assumptions, including assumptions described elsewhere in this release and those concerning general economic and market conditions, availability of working capital necessary for conducting Nova Leap's operations, availability of desirable acquisition targets and financing to fund such acquisitions, and Nova Leap's ability to integrate its acquired businesses and maintain previously achieved service hour and revenue levels, that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Risks that could cause results to differ from those stated in the forward-looking statements in this release include the impact of the COVID-19 pandemic or any recurrence, including staff and supply shortages, regulatory changes affecting the home care industry or government programs utilized by the Company (such as ERC), other unexpected increases in operating costs and competition from other service providers. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this press release are made as of the date of this release and included for the purpose of providing information about management's current expectations and plans relating to the future, and these statements may not be appropriate for other purposes. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company's filings with the Canadian securities regulators, which filings are available at .

本新聞稿中的某些資訊可能包含前瞻性陳述,例如有關未來擴張和成本節約的陳述,以及有關未來收購和業務增長的計劃,包括預期年化收入或年化經常性收入運行率增長以及預期的調整後綜合EBITDA利潤率。這些資訊基於當前的預期和假設,包括本新聞稿中其他部分描述的假設以及與一般經濟和市場條件有關的假設、開展Nova Leap運營所需的營運資金的可用性、理想收購目標的可用性和為此類收購提供資金的融資,以及Nova Leap整合其收購的業務並保持以前實現的服務時間和收入水準的能力。這些假設受重大風險和不確定性的影響,這些風險和不確定性很難預測。實際結果可能與任何前瞻性陳述中建議的結果大不相同。可能導致結果與本新聞稿中的前瞻性陳述所述不同的風險包括新冠肺炎疫情的影響或任何復發,包括員工和供應短缺、影響家庭護理行業的監管變化或公司正在實施的政府專案(如電子資源中心)、運營成本的其他意外增加以及來自其他服務提供商的競爭。本新聞稿中包含的所有前瞻性陳述,包括任何財務展望或面向未來的財務資訊,都是在本新聞稿發佈之日作出的,其中包括的目的是為了提供有關管理層目前對未來的期望和計劃的資訊,這些陳述可能不適用於其他目的。公司沒有義務更新前瞻性陳述,或更新實際結果可能與前瞻性陳述中反映的結果不同的原因,除非和直到適用於公司的證券法要求。識別風險和不確定性的其他資訊包含在公司提交給加拿大證券監管機構的檔案中,這些檔案可在

CAUTIONARY STATEMENT:

警示聲明:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

CONTACT: For further information:  Chris Dobbin, CPA, CA, ICD.D Director, President and CEO T: 902 401 9480     E:cdobbin@novaleaphealth.com
欲瞭解更多資訊,請聯繫:加州註冊會計師克裡斯·多賓,ICD.D董事,總裁,首席執行官電話:902 401 9480電子郵件:cdobbin@novaleapHealth.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論